Literature DB >> 4536364

The sickling process in relation to clinical manifestations.

A J Bellingham.   

Abstract

Knowledge of the detailed molecular mechanisms of the sickling process has led to an understanding of factors precipitating crises and hence allowed a reasoned approach to therapy. At present amelioration of the symptoms of sickle cell disease rests primarily on the avoidance and prompt treatment of the basic precipitating factors of the sickling process--fever, hypoxia, acidosis, and dehydration. Over the years many drugs have been claimed to have anti-sickling properties but have not stood the test of time. The current partial success of cyanate stems directly from this molecular knowledge. As further details of the site of intermolecular binding involved in the sickling process become available the possibility of developing more specific anti-sickling drugs becomes clearer.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4536364      PMCID: PMC1347200     

Source DB:  PubMed          Journal:  J Clin Pathol Suppl (R Coll Pathol)        ISSN: 0144-0330


  8 in total

1.  Effect of cyanate on sickling.

Authors:  A May; A J Bellingham; E R Huehns; G H Beaven
Journal:  Lancet       Date:  1972-03-25       Impact factor: 79.321

2.  Structure of sickled erythrocytes and of sickle-cell hemoglobin fibers.

Authors:  J T Finch; M F Perutz; J F Bertles; J Döbler
Journal:  Proc Natl Acad Sci U S A       Date:  1973-03       Impact factor: 11.205

3.  Acetylation of sickle cell hemoglobin by aspirin.

Authors:  I M Klotz; J W Tam
Journal:  Proc Natl Acad Sci U S A       Date:  1973-05       Impact factor: 11.205

4.  Oral urea therapy in children with sickle cell anemia.

Authors:  B H Lubin; F A Oski
Journal:  J Pediatr       Date:  1973-02       Impact factor: 4.406

5.  Stereochemistry of cooperative effects in haemoglobin.

Authors:  M F Perutz
Journal:  Nature       Date:  1970-11-21       Impact factor: 49.962

6.  Inhibition of CO2 combination and reduction of the Bohr effect in haemoglobin chemically modified at its alpha-amino groups.

Authors:  J V Kilmartin; L Rossi-Bernardi
Journal:  Nature       Date:  1969-06-28       Impact factor: 49.962

7.  Potassium cyanate as an inhibitor of the sickling of erythrocytes in vitro.

Authors:  A Cerami; J M Manning
Journal:  Proc Natl Acad Sci U S A       Date:  1971-06       Impact factor: 11.205

8.  Regulatory mechanisms of hemoglobin oxygen affinity in acidosis and alkalosis.

Authors:  A J Bellingham; J C Detter; C Lenfant
Journal:  J Clin Invest       Date:  1971-03       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.